EXPERT REACTION: Trial finds hydroxychloroquine doesn't stop people dying from COVID-19
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
A randomised clinical trial has found hydroxychloroquine is of no benefit for preventing death from COVID-19. The international RECOVERY Collaborative Group found in patients hospitalised with COVID-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. The results of the trial were previously released in June 2020 but this marks its publication in a peer-reviewed journal.
Journal/conference: New England Journal of Medicine
Link to research (DOI): 10.1056/NEJMoa2022926
Organisation/s: La Trobe University, The Kirby Institute for Infection and Immunity in Society, The University of Newcastle, The University of Sydney, The Australian National University, Australian Catholic University, UNSW, Bond University, University of Melbourne, Swinburne University, The RECOVERY Collaborative Group
Attachments:
Note: Not all attachments are visible to the general public
News for:
International
NSW
VIC
QLD
ACT
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.